Serum Ghrelin in Polycystic Ovary Syndrome

NCT ID: NCT02087410

Last Updated: 2014-03-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

84 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

measuring serum gherlin in polycystic ovary syndrome patients and compare it to healthy levels

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

two groups one healthy and other with pco measure ghrelin level in both of them to find relation between pco and ghrelin

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

study

patients with polycystic ovary syndrome

No interventions assigned to this group

control

healthy patients serves as control group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 12 months of infertility.
* Patients with polycystic ovarian syndrome according to Rotterdam criteria:

Exclusion Criteria

* Patients with hyperprolactinemia
* Patients with Cushing's syndrome
* Patients with Congenital or non-classical adrenal hyperplasia
* Patients with hormone secreting tumors.
* Patients with hormonal treatment in the last 3 months.
Minimum Eligible Age

20 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

amr hesham el etreby

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

amr hesham el etreby

resident maternity hospital

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

amr eletrby, MBBCH

Role: PRINCIPAL_INVESTIGATOR

ain shams universty maternity hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maternity Hospital

Cairo, Cairo Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

amr h eletreby, resident

Role: primary

0096659000850

amr h eletreby, resident

Role: backup

00966566255584

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ghrelin

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.